Milestone Plan Clause Samples

The Milestone Plan clause defines a schedule of key deliverables or project phases that must be completed by specified dates during the course of a contract. It typically outlines each milestone, the expected completion date, and any associated deliverables or performance criteria. For example, in a software development agreement, milestones might include the delivery of a prototype, completion of testing, and final product launch. This clause ensures that both parties have a clear, shared understanding of project timelines and progress expectations, helping to manage performance and reduce the risk of delays.
Milestone Plan. The Milestone Plan represents good faith projections of future financial performance of the Borrowers for the periods set forth therein. Such document has been prepared on the basis of the assumptions set forth therein, which the Borrowers believe are reasonable in light of current and reasonably foreseeable business conditions.
View SourceView Similar (4)
Milestone Plan. 6. 1The Contractor shall establish and comply with any implementation timetable and procedures set out in the Milestone Plan together with the test and assurance activities set out in any applicable Test Plan.
View Source
Milestone Plan. Replace Exhibit 8.4.1 with regard to the milestone plan for the 1G H70 by the new Exhibit 8.4.1 as attached to this Amendment.
View Source
Milestone Plan. The Milestone Plan represents good faith projections of future financial performance of KMC for the periods set forth therein. Such document has been prepared on the basis of the assumptions set forth therein, which KMC believes are reasonable in light of current and reasonably foreseeable business conditions.
View Source
Milestone Plan. The DEVELOPMENT WORK shall comprise also the efforts and activities set forth in Section 3 below and in the MILESTONE PLAN, and the Parties shall use reasonable efforts in carrying out the DEVELOPMENT WORK in accordance with the MILESTONE PLAN. The DEVELOPMENT WORK shall be carried out in close cooperation between the Parties and in a joint effort to keep cost and expenditures to a minimum.
View Source
Milestone Plan. Key Milestone Timing -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- -------------------------------------------------------------------------------- Very truly yours, By:____________________________ Title:_________________________ ACCEPTED: ____________ , 200____ Date:__________________________ By:______________________________ Title:___________________________ 16 ATTACHMENT 2.A STANDARD AGREEMENT FOR DISCLOSURE OF PROCTER & GAMB▇▇ ▇▇▇FIDENTIAL INFORMATION TO GENENCOR INTERNATIONAL, INC. Effective Date: ____________ In order to protect certain proprietary, confidential information which may be disclosed by the Procter & Gamb▇▇ ▇▇▇pany (herein "P&G") to Genencor International, Inc. (herein "GCOR"), the parties agree that: 1. The Discloser of confidential information hereunder is: The Recipient of confidential information hereunder is: 2. The parties' representatives for disclosing or receiving confidential information are: (P&G) (GCOR) 3. The confidential information disclosed under this Agreement is described as: ------------------------------------------------------------------------ ------------------------------------------------------------------------
View Source
Milestone Plan. ‌ 7.1 If the Commission exercises its rights under clause 5.2.3 to require Future Scheme Services the Contractor shall comply with the implementation timetable set out in the Milestone Plan, together with the test and assurance activities set out in any applicable Test Plan. 7.2 Any detailed version of the Milestone Plan approved by the Commission in accordance with clause 24 (Plan Approval Process) shall become the Milestone Plan and the Contractor shall provide the Services in accordance with that Milestone Plan. 7.3 All changes to the Milestone Plan shall be subject to the Change Control Procedure.
View Source

Related to Milestone Plan

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and: (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless: (1) it will suffer significant uncompensated economic or operational harm from the delay, (2) attainment of the same milestone has previously been delayed, or (3) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Milestone Event Milestone Payment [***] [***]